PDX Model Market Size, Share, Trends and Revenue | MarketsandMarkets

The patient-derived xenograft (PDX) model industry is poised for significant growth in the near future. These models, which involve implanting patient tumor samples into immunodeficient mice, have gained prominence for their ability to faithfully replicate human cancer biology and response to therapies.
Patient-Derived Xenograft / PDX Model Market [https://www.marketsandmarkets.com/Market-Reports/patient-derived-xenograft-model-market-121598251.html?utm_source=ABnewswire&utm_campaign=Paid&utm_content=Referral] in terms of revenue was estimated to be worth $426 million in 2023 and is poised to reach $839 million by 2028, growing at a CAGR of 14.5% from 2023 to 2028 according to a new report by MarketsandMarkets. Some of the prominent factors driving the growth of this market are the accuracy of drug testing, rising demand for personalized medicine, and the usefulness of PDX models to identify relevant biomarkers for disease diagnosis. However, significant operational costs associated with patient derived xenograft/ PDX model are expected to restrain market growth to a certain extent.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251&utm_source=ABnewswire&utm_campaign=Paid&utm_content=Referral]

Mouse model type accounted for the largest share of the patient-derived xenograft/ PDX model market.

Among the types, the patient-derived xenograft/ PDX model market is segmented into mouse model, and rat model. In 2023, the mouse model segment accounted for the largest share of the patient-derived xenograft/ PDX model market. Growth in this market segment can be attributed to biological similarities of the mice model with human tumors, and the availability of immunodeficient strains is expected to form the largest share segment in the patient derived xenograft/ PDX model market.

The respiratory tumor type segment is the fastest-growing segment of the patient derived xenograft/ PDX model market.

In 2023, the respiratory tumor type segment accounted for the fastest-growing share of the tumor type segment of the patient derived xenograft/ PDX model market. Market growth can largely be attributed to the rising prevalence of lung cancer. The market is also driven by increasing focus on the drug development of respiratory tumor models after the COVID-19 pandemic.

Asia Pacific: The fastest-growing region in the patient derived xenograft/ PDX model market.

The Asia Pacific patient derived xenograft/ PDX model market is projected to grow at the highest CAGR during the forecast period, mainly due to increasing awareness of precision medicine and a rise in the number of drug development processes. The Asian market has also garnered significant attention from global players due to the increasing pharmaceutical R&D spending, and the growing trend of outsourcing drug discovery services.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=121598251 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=121598251&utm_source=ABnewswire&utm_campaign=Paid&utm_content=Referral]

Patient-Derived Xenograft / PDX Model Market Dynamics:

Drivers:

* Growing demand for personalized medicine

Restraints:

* FDA's announcement to discontinue animal models for clinical trials

Opportunities:

* Emergence of CRISPR in biomedical research

Challenge:

* Development of alternative animal testing methods

Key Market Players of Patient-Derived Xenograft / PDX Model Industry:

The market for patient-derived xenograft/ PDX models is highly fragmented, with key players strategizing to capture a majority of the market. Prominent players in the market are JSR Corporation (Japan), Wuxi Apptec (China), The Jackson Laboratory (US), Charles River Laboratories International, Inc. (US), Taconic Biosciences, Inc. (US), Oncodesign Precision Medicine (France), Inotiv, Inc. (US), Pharmatest Services (Finland), Hera BioLabs (US), EPO Berlin-Buch GmbH (Germany), Xentech (France), Urosphere (France), Altogen Labs (US), Abnova Corporation (US), Genesis Biotechnology Group (US), Biocytogen Pharmaceuticals Co., Ltd. (China), Creative Animodel (US), BioDuro-Sundia (US), Aragen Life Sciences (India), Shanghai LIDE Biotech Co., Ltd. (China), Certis Oncology Solutions (US), InnoSer (Netherlands), IVRS AB (Sweden), Beijing IDMO Co. Ltd. (China), and Shanghai Chempartner Co. Ltd. (China).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=121598251 [https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=121598251&utm_source=ABnewswire&utm_campaign=Paid&utm_content=Referral]

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pdx-model-market-size-share-trends-and-revenue-marketsandmarkets]
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/patient-derived-xenograft-model-market-121598251.html



This release was published on openPR.